Obese AdolescentsNCT07103889
Effect of Acute Exercise on Biochemical Parameters in Normal-Weight and Overweight/Obese Adolescent.
A study testing Spartacus Test in people with Obese Adolescents and Overweight, run by High Institute of Sports and Physical Education of Kef at 1 site in Tunisia.
Trial summary
The goal of this interventional clinical trial is to compare the acute physiological and biochemical responses to maximal physical exercise (Spartacus test). in two groups of adolescent girls: in normal-weight and overweight/obese adolescent. Read more about this study
- Who is it for?
- Ages 13 to 18 years, women only
- Conditions the study is for
- Obese Adolescents, Overweight
- What is being tested?
- Spartacus Test
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteTunisia
- Study dates
- 10 Aug 2025to 13 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 18 years
- Women only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Female,
- Aged 14-18 years
- BMI between the 5th and <85th percentile for age (normal-weight group), or BMI ≥ 85th percentile for age (overweight/obese group)
- No chronic illness or contraindication to exercise
- No regular medication use
- Written informed consent from participant and parent/legal guardian
Who cannot join
- Presence of chronic diseases (diabetes, thyroid disorders, etc.)
- Musculoskeletal or cardiovascular contraindications to maximal exercise
- Pregnancy
- Recent infection or inflammation
- Use of anti-inflammatory or hormonal medications
Trial locations and contacts
1 site in 1 country.
Tunisia1 site
High Institute of Sports and Physical Education of Kef
Boulifa, Kef Governorate, 7100
About this study
Official title: Assessment of Biochemical, Metabolic, Inflammatory, and Hematological Parameters Following Acute Exercise in Normal-Weight and Overweight/Obese Adolescent Girls.
The goal of this interventional clinical trial is to compare the acute physiological and biochemical responses to maximal physical exercise (Spartacus test). in two groups of adolescent girls: in normal-weight and overweight/obese adolescent. The main question it aims to answer:
- Does Spartacus test significantly alter glucose metabolism and lipid profile in normal-weight and overweight/obese adolescent?
- How do inflammatory markers such as C-Reactive Protein [CRP], Erythrocyte Sedimentation Rate [ESR], respond immediately after and 30 minutes following maximal effort?
- Are there significant changes in liver enzymes (Aspartate Aminotransferase [AST], Alanine Aminotransferase [ALT]), muscle damage indicators (creatine kinase [CK], Lactate Dehydrogenase [LDH]), and electrolyte balance post-exercise? Participants will undergo a baseline blood draw before performing the Spartacus test , a progressive maximal exercise test. Blood samples will then be collected immediately after the test and again 30 minutes post-exercise to evaluate changes in: Glucose metabolism (fasting glucose), Lipid profile (total cholesterol, High-Density Lipoprotein [HDL], Low-Density Lipoprotein [LDL], triglycerides), Liver and muscle enzymes (Aspartate Aminotransferase [AST], Alanine Aminotransferase [ALT], Creatine kinase [CK], Lactate Dehydrogenase [LDH]), Renal function markers (creatinine, urea), Inflammatory markers (C-Reactive Protein [CRP], Erythrocyte Sedimentation Rate [ESR]), Hematological profile (complete blood count: White Blood Cells [WBC], Red Blood Cells [RBC], Hemoglobin [Hb], Hematocrit [Hct], platelets), Electrolytes (sodium, potassium, chloride), Uric acid, calcium, phosphorus, magnesium, iron.
Read the detailed description
This is an interventional clinical trial designed to evaluate the acute physiological and biochemical responses to maximal physical exercise (Spartacus test) in normal-weight and overweight/obese adolescent. The study aims to investigate how a single session Spartacus test affects key metabolic, inflammatory, hepatic, muscular, renal, and hematological parameters.
Participants will be divided into two groups:
Group 1: Normal-weight adolescent girls Adolescent girls with a body mass index (BMI) between the 5th and <85th percentile for age.
Group 2: Overweight/obese adolescent girls Adolescent girls with a BMI ≥ 85th percentile for age. The protocol involves running on a simulated rectangular course (750 m²), with increasing speed every 3 minutes (starting at 7 km/h and increasing by 1 km/h each stage). Participants must reach a marked cone corresponding to the new speed within 15 seconds, followed by a 15-second rest period before the next stage begins. The test continues until voluntary exhaustion or inability to maintain the required pace.
Blood samples will be collected at three time points:
Baseline (Time 0): Before the start of the exercise. Immediately post-exercise (Time 1): Within 5 minutes after completion of the test.
30 minutes post-exercise (Time 2): To assess early recovery kinetics.
The following biomarkers will be measured at each time point:
Metabolic profile: Fasting glucose, lipid panel (total cholesterol, HDL, LDL, triglycerides), uric acid Liver function: AST, ALT, LDH, CK Renal function: Creatinine, urea Inflammatory markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) Hematological profile: Complete blood count (CBC), including white blood cell differential, hemoglobin, hematocrit, red blood cell indices, and platelet count Electrolytes: Sodium (Na⁺), potassium (K⁺), chloride (Cl-) Minerals and trace elements: Calcium, phosphorus, magnesium, iron
- Conditions
- Obese Adolescents, Overweight
- Being tested
- Spartacus Test
- Keywords
- Adolescent, Maximal Exercise, Blood Biomarkers, Liver Enzymes, Lipid Profile, Renal Function, obesity, overweight, Normal-weight
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spartacus TestBehavioural
The Spartacus test was conducted on a 750 m (75 × 10 m) rectangular course marked with cones at regular intervals to indicate different speeds (from 7 to 18 km/h). Each participant began running at 7 km/h, with speed increasing by 1 km/h every three minutes.During the 3-minute intervals (for each speed stage), participants had 15 seconds to reach the corresponding marker, followed by 15 seconds of rest. Participants had to adjust their running pace to reach the target cone in synchrony with an audio signal. The test ended when a participant failed to reach the next cone within the given time. This test is validated for assessing maximal aerobic capacity (MAS) in obese adolescents. During the Spartacus test, maximal heart rate (HRmax) was recorded using a heart rate monitor (S810; Polar, Kempele, Finland).
| Study group | Role | What they receive |
|---|---|---|
| Normal-weight adolescent girls | Experimental | Body mass index (BMI) between the 5th and <85th percentile for age. Receives: Behavioral: Spartacus Test |
| Overweight/obese adolescent | Experimental | BMI ≥ 85th percentile for age. Receives: Behavioral: Spartacus Test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of Blood Glucose (mg/dL)
Blood glucose levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
iron
Serum iron concentration will be measured using a colorimetric assay in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Total Cholesterol (mg/dL)
Total cholesterol will be assessed using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of HDL Cholesterol (mg/dL)
HDL cholesterol will be analyzed using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Triglycerides (mg/dL)
Triglyceride levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Calculated LDL Cholesterol (mg/dL)
LDL cholesterol will be estimated using the Friedewald formula based on total cholesterol, HDL cholesterol, and triglycerides measured via enzymatic colorimetric assays in a certified clinical laboratory.
LDL-C (mg/dL)=Cholesterol total-HDL Cholesterol-( Triglycerides /5)
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of C-Reactive Protein (CRP) (mg/L)
CRP levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Erythrocyte Sedimentation Rate (ESR) (mm/hr)
ESR will be determined using standard laboratory methods in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Aspartate Aminotransferase (AST) (U/L)
AST levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Alanine Aminotransferase (ALT) (U/L)
ALT levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Lactate Dehydrogenase (LDH) (U/L)
LDH levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Creatine Kinase (CK) (U/L)
CK levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Creatinine (mg/dL)
Creatinine levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Urea (mg/dL)
Urea levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Concentration of Serum Uric Acid (mg/dL)
Serum concentrations of uric acid will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Glomerular Filtration Rate
The glomerular Filtration Rate (GFR) has been computed using the Cockcroft formula, as follows: GFR (mL/min) = [(140 - age) × weight ×0.85]/( Serum Creatinine× 72).
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
White Blood Cell Count (WBC) (10³/µL)
WBC will be measured using standard hematology analyzers in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Red Blood Cell Count (RBC) (10³/µL)
RBC will be measured using standard hematology analyzers in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Hemoglobin Concentration (Hb) (g/dL)
Hb concentration will be measured using standard hematology analyzers in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Hematocrit (Hct) (%)
Hematocrit will be measured using standard hematology analyzers in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Platelet Count (10³/µL)
Platelet count will be measured using standard hematology analyzers in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Mean Corpuscular Hemoglobin Content (MCH) (pg)
Blood levels of mean corpuscular hemoglobin content will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Mean Hemoglobin Concentration (MCHC) (g/dL)
Blood levels of mean hemoglobin concentration will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Mean Corpuscular Volume (MCV) (fL)
Blood levels of mean corpuscular volume will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Plasma volume variations
Plasma volume variations (PVV) was calculated based on measured hematocrit (Ht) and hemoglobin (Hb) valuesaccording to the method developed by Costill and Fink (1974). %PVV=100 ×[(HbA/HbB) ×(100 - HtB) / (100 - HtA)] -
1, where 0 is the value measured before exercise and 1 is the value measured after exercise.
Measured: Plasma volume variations (PVV) was calculated Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Sodium Concentration (mmol/L)
Serum sodium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Potassium Concentration (mmol/L)
Serum potassium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Chloride Concentration (mmol/L)
Serum chloride levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Calcium Concentration (mmol/L)
Serum calcium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Phosphorus Concentration (mmol/L)
Serum phosphorus levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Magnesium Concentration (mg/dL)
Serum magnesium concentration will be determined using a spectrophotometric colorimetric method in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum Iron Concentration (µg/dL)
Serum iron concentration will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Measured: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start10 Aug 2025
- Primary completion13 Aug 2025
- Study completion13 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obese AdolescentsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- High Institute of Sports and Physical Education of Kef
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wissal Abassi, High Institute of Sports and Physical Education of Kef
- Investigators
- Wissal abassi, Dr, Principal investigator, Research Unit "Sport Sciences, Health and Movement"(UR22JS01) High Institute of Sport and Physical Education of Kef, University of Jendouba, 7100 Kef, Tunisia.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07103889
- Sponsor's protocol ID
- ACUTE-EXER-OBESE-2025
- Status last verified
- Jul 2025
- First submitted
- 18 Jul 2025
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Biochemical, Metabolic, Inflammatory, and Hematological Parameters Following Acute Exercise in Normal-Weight and Overweight/Obese Adolescent Girls.
- ClinicalTrials.gov ID
- NCT07103889
- Acronym / sponsor ID
- ACUTE-EXER-OBESE-2025
- Conditions
- Obese Adolescents, Overweight
- Keywords
- Adolescent, Maximal Exercise, Blood Biomarkers, Liver Enzymes, Lipid Profile, Renal Function, obesity, overweight
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- High Institute of Sports and Physical Education of KefUniversity, hospital or other
- Study start
- 10 Aug 2025 (actual)
- Primary completion
- 13 Aug 2025 (actual)
- Study completion
- 13 Aug 2025 (actual)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional clinical trial is to compare the acute physiological and biochemical responses to maximal physical exercise (Spartacus test). in two groups of adolescent girls: in normal-weight and overweight/obese adolescent. The main question it aims to answer:
- Does Spartacus test significantly alter glucose metabolism and lipid profile in normal-weight and overweight/obese adolescent?
- How do inflammatory markers such as C-Reactive Protein [CRP], Erythrocyte Sedimentation Rate [ESR], respond immediately after and 30 minutes following maximal effort?
- Are there significant changes in liver enzymes (Aspartate Aminotransferase [AST], Alanine Aminotransferase [ALT]), muscle damage indicators (creatine kinase [CK], Lactate Dehydrogenase [LDH]), and electrolyte balance post-exercise? Participants will undergo a baseline blood draw before performing the Spartacus test , a progressive maximal exercise test. Blood samples will then be collected immediately after the test and again 30 minutes post-exercise to evaluate changes in: Glucose metabolism (fasting glucose), Lipid profile (total cholesterol, High-Density Lipoprotein [HDL], Low-Density Lipoprotein [LDL], triglycerides), Liver and muscle enzymes (Aspartate Aminotransferase [AST], Alanine Aminotransferase [ALT], Creatine kinase [CK], Lactate Dehydrogenase [LDH]), Renal function markers (creatinine, urea), Inflammatory markers (C-Reactive Protein [CRP], Erythrocyte Sedimentation Rate [ESR]), Hematological profile (complete blood count: White Blood Cells [WBC], Red Blood Cells [RBC], Hemoglobin [Hb], Hematocrit [Hct], platelets), Electrolytes (sodium, potassium, chloride), Uric acid, calcium, phosphorus, magnesium, iron.
Detailed description
This is an interventional clinical trial designed to evaluate the acute physiological and biochemical responses to maximal physical exercise (Spartacus test) in normal-weight and overweight/obese adolescent. The study aims to investigate how a single session Spartacus test affects key metabolic, inflammatory, hepatic, muscular, renal, and hematological parameters.
Participants will be divided into two groups:
Group 1: Normal-weight adolescent girls Adolescent girls with a body mass index (BMI) between the 5th and <85th percentile for age.
Group 2: Overweight/obese adolescent girls Adolescent girls with a BMI ≥ 85th percentile for age. The protocol involves running on a simulated rectangular course (750 m²), with increasing speed every 3 minutes (starting at 7 km/h and increasing by 1 km/h each stage). Participants must reach a marked cone corresponding to the new speed within 15 seconds, followed by a 15-second rest period before the next stage begins. The test continues until voluntary exhaustion or inability to maintain the required pace.
Blood samples will be collected at three time points:
Baseline (Time 0): Before the start of the exercise. Immediately post-exercise (Time 1): Within 5 minutes after completion of the test.
30 minutes post-exercise (Time 2): To assess early recovery kinetics.
The following biomarkers will be measured at each time point:
Metabolic profile: Fasting glucose, lipid panel (total cholesterol, HDL, LDL, triglycerides), uric acid Liver function: AST, ALT, LDH, CK Renal function: Creatinine, urea Inflammatory markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) Hematological profile: Complete blood count (CBC), including white blood cell differential, hemoglobin, hematocrit, red blood cell indices, and platelet count Electrolytes: Sodium (Na⁺), potassium (K⁺), chloride (Cl-) Minerals and trace elements: Calcium, phosphorus, magnesium, iron
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal-weight adolescent girls | Experimental | Behavioral: Spartacus TestBody mass index (BMI) between the 5th and <85th percentile for age. |
| Overweight/obese adolescent | Experimental | Behavioral: Spartacus TestBMI ≥ 85th percentile for age. |
Who may qualify
- Ages
- 13 to 18 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Female,
- Aged 14-18 years
- BMI between the 5th and <85th percentile for age (normal-weight group), or BMI ≥ 85th percentile for age (overweight/obese group)
- No chronic illness or contraindication to exercise
- No regular medication use
Key exclusion criteria (5 listed)
- Presence of chronic diseases (diabetes, thyroid disorders, etc.)
- Musculoskeletal or cardiovascular contraindications to maximal exercise
- Pregnancy
- Recent infection or inflammation
- Use of anti-inflammatory or hormonal medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spartacus TestThe Spartacus test was conducted on a 750 m (75 × 10 m) rectangular course marked with cones at regular intervals to indicate different speeds (from 7 to 18 km/h). Each participant began running at 7 km/h, with speed increasing by 1 km/h every three minutes.During the 3-minute intervals (for each speed stage), participants had 15 seconds to reach the corresponding marker, followed by 15 seconds of rest. Participants had to adjust their running pace to reach the target cone in synchrony with an audio signal. The test ended when a participant failed to reach the next cone within the given time. This test is validated for assessing maximal aerobic capacity (MAS) in obese adolescents. During the Spartacus test, maximal heart rate (HRmax) was recorded using a heart rate monitor (S810; Polar, Kempele, Finland). | Behavioural | Normal-weight adolescent girls, Overweight/obese adolescent |
Primary outcome
Concentration of Blood Glucose (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Blood glucose levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
iron
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum iron concentration will be measured using a colorimetric assay in a certified clinical laboratory.
Concentration of Total Cholesterol (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Total cholesterol will be assessed using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of HDL Cholesterol (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
HDL cholesterol will be analyzed using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Triglycerides (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Triglyceride levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Calculated LDL Cholesterol (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
LDL cholesterol will be estimated using the Friedewald formula based on total cholesterol, HDL cholesterol, and triglycerides measured via enzymatic colorimetric assays in a certified clinical laboratory. LDL-C (mg/dL)=Cholesterol total-HDL Cholesterol-( Triglycerides /5)
Concentration of C-Reactive Protein (CRP) (mg/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
CRP levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Erythrocyte Sedimentation Rate (ESR) (mm/hr)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
ESR will be determined using standard laboratory methods in a certified clinical laboratory.
Concentration of Aspartate Aminotransferase (AST) (U/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
AST levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Alanine Aminotransferase (ALT) (U/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
ALT levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Lactate Dehydrogenase (LDH) (U/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
LDH levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Creatine Kinase (CK) (U/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
CK levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Creatinine (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Creatinine levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Urea (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Urea levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Concentration of Serum Uric Acid (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum concentrations of uric acid will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Glomerular Filtration Rate
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
The glomerular Filtration Rate (GFR) has been computed using the Cockcroft formula, as follows: GFR (mL/min) = [(140 - age) × weight ×0.85]/( Serum Creatinine× 72).
White Blood Cell Count (WBC) (10³/µL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
WBC will be measured using standard hematology analyzers in a certified clinical laboratory.
Red Blood Cell Count (RBC) (10³/µL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
RBC will be measured using standard hematology analyzers in a certified clinical laboratory.
Hemoglobin Concentration (Hb) (g/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Hb concentration will be measured using standard hematology analyzers in a certified clinical laboratory.
Hematocrit (Hct) (%)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Hematocrit will be measured using standard hematology analyzers in a certified clinical laboratory.
Platelet Count (10³/µL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Platelet count will be measured using standard hematology analyzers in a certified clinical laboratory.
Mean Corpuscular Hemoglobin Content (MCH) (pg)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Blood levels of mean corpuscular hemoglobin content will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory.
Mean Hemoglobin Concentration (MCHC) (g/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Blood levels of mean hemoglobin concentration will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory.
Mean Corpuscular Volume (MCV) (fL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Blood levels of mean corpuscular volume will be measured from a 5 ml blood sample and analyzed using a multichannel automated hematology analyzer in a certified clinical laboratory
Plasma volume variations
Time frame: Plasma volume variations (PVV) was calculated Immediately after Spartacus, and 30 minutes post-Spartacus.
Plasma volume variations (PVV) was calculated based on measured hematocrit (Ht) and hemoglobin (Hb) valuesaccording to the method developed by Costill and Fink (1974). %PVV=100 ×[(HbA/HbB) ×(100 - HtB) / (100 - HtA)] - 1, where 0 is the value measured before exercise and 1 is the value measured after exercise.
Serum Sodium Concentration (mmol/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum sodium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Serum Potassium Concentration (mmol/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum potassium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Serum Chloride Concentration (mmol/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum chloride levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Serum Calcium Concentration (mmol/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum calcium levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Serum Phosphorus Concentration (mmol/L)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum phosphorus levels will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Serum Magnesium Concentration (mg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum magnesium concentration will be determined using a spectrophotometric colorimetric method in a certified clinical laboratory.
Serum Iron Concentration (µg/dL)
Time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.
Serum iron concentration will be measured using enzymatic colorimetric assays in a certified clinical laboratory.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
Related trials for Obese Adolescents
Not yet recruiting
Nutritional Responses to Acute Exercise Performed on the LipoxMax in Obese Adolescents
Weight Gain, Weight Loss
RecruitingObservational study
Associations Between Physical Activity and Sedentary Behavior Profiles and Carotid Intima-media Thickness in Adolescents With Obesity
Obese Adolescents
Recruiting
Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)
PCOS (Polycystic Ovary Syndrome), Obese Adolescents
RecruitingObservational study
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Obesity and Overweight, Obese Adolescents
Not yet recruiting
A Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention
Obesity & Overweight, Obese Adolescents
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wissal abassi, Dr principal investigator
Research Unit "Sport Sciences, Health and Movement"(UR22JS01) High Institute of Sport and Physical Education of Kef, University of Jendouba, 7100 Kef, Tunisia.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spartacus Test in people with Obese Adolescents and Overweight, run by High Institute of Sports and Physical Education of Kef at 1 site in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of Blood Glucose (mg/dL) (time frame: At baseline, Immediately after Spartacus, and 30 minutes post-Spartacus.). The study lists 32 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025; AzTrials last refreshed its copy on 4 Nov 2026.